Literature DB >> 11737471

Lymphatic ascites following lymphadenectomy for gynecological malignancy.

C S Krishnan1, P T Grant, G Robertson, N F Hacker.   

Abstract

Seven patients seen between January 1995 and December 1998 developed symptomatic lymphatic ascites following either pelvic or para-aortic lymph node dissection. The incidence of symptomatic lymphatic ascites during this 4-year period was 2.7% (7 of 263 cases). The accumulation of ascites postoperatively was associated with a prolonged postoperative ileus, abdominal pain, and extended postoperative hospitalization. Once the condition was recognized, abdominal paracentesis resulted in rapid improvement of symptoms in two patients but repeated paracenteses were required for a further two patients who had significant complications as a result of these procedures. Two patients improved following spontaneous drainage of a large amount of ascites per vagina and did not require further intervention. The final patient settled with observation only. This condition can be difficult to recognize and is a potential cause of significant postoperative morbidity.

Entities:  

Mesh:

Year:  2001        PMID: 11737471     DOI: 10.1046/j.1525-1438.2001.01050.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Recurrent lymphatic ascites in a patient cured of cervical carcinoma.

Authors:  John P Micha; Alberto A Mendivil; John S Cupp; Bram H Goldstein
Journal:  Gynecol Oncol Case Rep       Date:  2012-05-16

2.  Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study.

Authors:  Li Chen; Liang Lin; Ling Li; Zuolian Xie; Haixin He; Cuibo Lin; Jian Chen; An Lin
Journal:  BMC Cancer       Date:  2021-11-18       Impact factor: 4.430

Review 3.  A review of the postoperative lymphatic leakage.

Authors:  Shulan Lv; Qing Wang; Wanqiu Zhao; Lu Han; Qi Wang; Nasra Batchu; Qurat Ulain; Junkai Zou; Chao Sun; Jiang Du; Qing Song; Qiling Li
Journal:  Oncotarget       Date:  2017-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.